Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

The FLAURA trial established osimertinib, a third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell …

Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non …

The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
has significantly improved the prognosis of advanced non-small cell lung cancer (NSCLC) …

Importance The survival of patients with advanced non–small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …

Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …

First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …